388 related articles for article (PubMed ID: 18758435)
1. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model.
Jeong JS; Lee SW; Hong SH; Lee YJ; Jung HI; Cho KS; Seo HH; Lee SJ; Park S; Song MS; Kim CM; Kim IH
Clin Cancer Res; 2008 Jan; 14(1):281-90. PubMed ID: 18172280
[TBL] [Abstract][Full Text] [Related]
3. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.
Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW
Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278
[TBL] [Abstract][Full Text] [Related]
4. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme.
Song MS; Lee SW
FEBS Lett; 2006 Sep; 580(21):5033-43. PubMed ID: 16949075
[TBL] [Abstract][Full Text] [Related]
5. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme.
Song MS; Jeong JS; Cho KS; Lee SW
Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843
[TBL] [Abstract][Full Text] [Related]
6. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement.
Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW
Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
8. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
9. Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme.
Kwon BS; Jeong JS; Won YS; Lee CH; Yoon KS; Hyung Jung M; Kim IH; Lee SW
J Gene Med; 2011 Feb; 13(2):89-100. PubMed ID: 21322101
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
Gu J; Kagawa S; Takakura M; Kyo S; Inoue M; Roth JA; Fang B
Cancer Res; 2000 Oct; 60(19):5359-64. PubMed ID: 11034071
[TBL] [Abstract][Full Text] [Related]
11. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.
Hong SH; Jeong JS; Lee YJ; Jung HI; Cho KS; Kim CM; Kwon BS; Sullenger BA; Lee SW; Kim IH
Mol Ther; 2008 Jan; 16(1):74-80. PubMed ID: 17700543
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
13. In vivo reprogramming of human telomerase reverse transcriptase (hTERT) by trans-splicing ribozyme to target tumor cells.
Lee SJ; Lee SW; Jeong JS; Kim IH
Methods Mol Biol; 2010; 629():307-21. PubMed ID: 20387158
[TBL] [Abstract][Full Text] [Related]
14. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
17. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
Gu J; Andreeff M; Roth JA; Fang B
Gene Ther; 2002 Jan; 9(1):30-7. PubMed ID: 11850720
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
Komata T; Kondo Y; Kanzawa T; Hirohata S; Koga S; Sumiyoshi H; Srinivasula SM; Barna BP; Germano IM; Takakura M; Inoue M; Alnemri ES; Shay JW; Kyo S; Kondo S
Cancer Res; 2001 Aug; 61(15):5796-802. PubMed ID: 11479218
[TBL] [Abstract][Full Text] [Related]
19. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter.
He LF; Wang YG; Xiao T; Zhang KJ; Li GC; Gu JF; Chu L; Tang WH; Tan WS; Liu XY
Cancer Lett; 2009 Dec; 286(2):196-205. PubMed ID: 19564073
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]